Development of a siRNA anticancer drug using sustained release microsphere injection

DOI Web Site 21 References
  • Kanazawa Takanori
    Laboratory of Pharmaceutics and Drug Delivery, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Takashima Yuuki
    Laboratory of Pharmaceutics and Drug Delivery, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Okada Hiroaki
    Laboratory of Pharmaceutics and Drug Delivery, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Bibliographic Information

Other Title
  • バイオ素材による創薬とＤＤＳ　　徐放性マイクロスフェア型注射剤の開発によるｓｉＲＮＡ制がん剤の創薬
  • 徐放性マイクロスフェア型注射剤の開発によるsiRNA制がん剤の創薬
  • ジョホウセイ マイクロスフェアガタ チュウシャザイ ノ カイハツ ニ ヨル siRNA セイガンザイ ノ ソウヤク

Search this article

Abstract

In order to develop a siRNA drug, chemical modification and formulation of siRNA are required. We prepared long-term sustained release microspheres (msp) encapsulating siRNA with a cationic carrier. The siRNA msp achieved a persistent suppression of tumor growth in S-180 bearing mice.

Journal

  • Drug Delivery System

    Drug Delivery System 23 (5), 544-552, 2008

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top